Context Therapeutics (NASDAQ:CNTX) Stock Moved Up to Hold by Zacks Research

Context Therapeutics (NASDAQ:CNTX) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday, Zacks reports.

A number of other equities analysts also recently commented on CNTX. Citigroup reiterated an “outperform” rating on shares of Context Therapeutics in a research note on Thursday, August 6th. Wall Street Zen lowered Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. Weiss Ratings upgraded Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, October 15th. Finally, Lifesci Capital cut Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Context Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $6.40.

Context Therapeutics Price Performance

Shares of CNTX stock opened at $0.22 on Tuesday. Context Therapeutics has a 1-year low of $0.18 and a 1-year high of $3.62. The firm has a fifty day moving average of $0.29 and a two-hundred day moving average of $1.39.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Tuesday, November 10th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03. On average, research analysts forecast that Context Therapeutics will post -0.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Octagon Capital Advisors LP bought a new stake in Context Therapeutics during the first quarter valued at $13,755,000. Blue Owl Capital Holdings LP acquired a new stake in shares of Context Therapeutics during the second quarter worth $1,625,000. BlackRock Inc. bought a new position in shares of Context Therapeutics in the 2nd quarter worth about $3,417,000. Bank of New York Mellon Corp bought a new position in shares of Context Therapeutics in the 2nd quarter worth about $61,000. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Context Therapeutics by 8,907.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 671,074 shares of the company’s stock valued at $202,000 after buying an additional 663,624 shares during the period. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc. (NASDAQ:CNTX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for solid tumors. The company’s approach is centered on T-cell-engaging bispecific antibodies, which are designed to direct the body’s immune cells toward cancer cells expressing specific tumor-associated antigens. Context’s lead program is CTIM-76, an investigational bispecific antibody that targets Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is being developed for patients with CLDN6-positive advanced solid tumors, including ovarian, endometrial, testicular and other cancers.